Memorial Sloan Kettering Cancer Center
@MSKCancerCenter
Where you’re treated first, matters. To make an appointment: 877-871-9362
- The @US_FDA has expanded approval of Pluvicto® (¹⁷⁷Lu-PSMA-617) as an initial treatment for people with metastatic prostate cancer whose tumors are positive for the PSMA protein. The approval is based on results from the phase 3 PSMAddition trial, led in the U.S. by MSK
- (1/2) MSK researchers have identified ZFP36L2, a protein that connects the gut’s damage-sensing system to the ability of cells to change identities and repair an injury. The study, published in @Nature, was led by @KarunaMDPhD and @Qingwen_J. bit.ly/3RR5ukL
- Inherited #BRCA1 and #BRCA2 mutations may affect how breast tumors evolve and respond to treatment, according to a study from MSK and collaborators involving genomic data from more than 5,800 patients. MSK breast medical oncologist @PedramRazaviMD spoke with @TargetedOnc about
- Top news! MSK is ranked #2 in the nation for cancer care, the #1 cancer center in New York, and #1 for urology care for the 4th year in a row, via the @usnews 2026-2027 Best Hospitals list. Learn more: bit.ly/454gf6c
